Clinical trials: Osteoporosis
Osteoporosis
Denosumab Safety Assessment in Multiple Observational Databases
This is a prospective open-cohort study with annual assessment and reporting of descriptive findings from 5 secondary data sources, US Medicare, Optum Research Database (formerly United HealthCare), Scandinavian national health…
- Trial name
- NCT02520362
- Testing
- denosumab, bisphosphonate
- Volunteers
- 517,991 people
- Sponsor
- Amgen
Osteopenia, Osteoporosis
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
The primary objective of this study is to compare the urinary excretion of 14C-labeled risedronate and alendronate over 28 days.
- Trial name
- NCT00577850
- Testing
- risedronate, alendronate
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Warner Chilcott
Calcium, Osteoporosis
A Study of Amorphous Calcium Carbonate in Postmenopausal Women
Using the FREEDOM substudy as a benchmark, evaluate the effects of amorphous calcium carbonate (ACC) on bone mineral density (BMD) in postmenopausal women, both with and without the combination of Denosumab treatment.
- Conditions
- Calcium, Osteoporosis, Bone Mineral Density, Bone Turnover Marker
- Trial name
- NCT06728462
- Testing
- Amorphous calcium carbonate
- Where
- Taiwan
- Volunteers
- 205 people
- Sponsor
- Universal Integrated Corp.
Osteoporosis
An Observational Study Assessing Effects in Patients With Combination Therapy With Raloxifene/Cholecalciferol
This study examines quality of life and patient satisfaction in postmenopausal women receiving raloxifene to prevent/treat osteoporosis, and vitamin D to reduce risk of fracture using clinical practice data.
- Trial name
- NCT04788290
- Testing
- Observational
- Where
- South Korea
- Volunteers
- 3,907 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Postmenopausal, Osteopenia
Effects of Denosumab on the Pharmacokinetics of Etanercept
The primary objective of the study was to characterize the effects of a single dose of denosumab on the pharmacokinetics (PK) of etanercept in postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis…
- Conditions
- Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
- Trial name
- NCT01294397
- Testing
- Etanercept, Denosumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Amgen
Postmenopausal Osteoporosis
A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen
The purpose of this study is to determine which of two delivery methods of Parathyroid Hormone (PTH) is preferred by patients after 14 days of use for each.
- Trial name
- NCT02478879
- Testing
- ZP-PTH, FORTEO
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Zosano Pharma Corporation
Post-Menopausal Osteoporosis
BONCURE Study: A Study of Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis on Bisphosphonate Therapy.
This single arm study will assess participant preference for monthly Bonviva, versus daily or weekly alendronate or risedronate, in the treatment of postmenopausal osteoporosis.
- Trial name
- NCT00545779
- Testing
- Ibandronate
- Where
- 32 sites in Albania, Bosnia and Herzegovina and 4 more
- Volunteers
- 677 people
- Sponsor
- Hoffmann-La Roche
Osteopenia, Osteoporosis
Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
This study is designed to provide information on the safety, tolerability, pharmacokinetics (PK) and bone biomarker response following multiple BPS804 administration in multiple dosing regimens.
- Trial name
- NCT01406548
- Testing
- BPS804 20mg/Kg
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Osteopenia, Osteoporosis
Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.
The purpose of this study is to determine the safety and tolerability of RN564 in women with osteopenia and healthy men.
- Conditions
- Osteopenia, Osteoporosis, Bone Disease
- Trial name
- NCT01293487
- Testing
- RN564
- Where
- 8 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effects of Single and Multiple-Doses of ATF936 and AXT914 Administered Orally in Healthy Subjects.
This is a first-in-human study and is designed to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic effects of a single and multiple-doses of ATF936 and AXT914 administered orally in healthy subjects.
- Trial name
- NCT00417261
- Testing
- ATF936, AXT914
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Novartis
Osteoporosis
Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice
This survey is conducted for preparing application material for re examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, and assessing the safety and efficacy profiles of VIVIANT in usual practice…
- Trial name
- NCT01793142
- Testing
- Viviant
- Where
- 60 sites in South Korea
- Volunteers
- 3,430 people
- Sponsor
- Pfizer
Postmenopausal Osteoporosis
G56W1 in Women With Postmenopausal Osteoporosis
This study will assess the pharmacokinetics and safety and explore therapeutic effects with once-weekly recombinant human parathyroid hormone for injection ( 1-34 ) ( G56W1 ) in women with post-menopausal osteoporosis .The…
- Trial name
- NCT03720886
- Testing
- rhPTH（1-34） 28.2μg, rhPTH（1-34） 56.5μg, teriparatide acetate(Teribone™)
- Where
- 9 sites in China
- Volunteers
- 148 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Osteopenia, Osteoporosis
Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis
The primary objective was to describe the safety and tolerability of up to 10 years or 7 years denosumab administration as measured by adverse event monitoring, immunogenicity and safety laboratory parameters in participants who…
- Trial name
- NCT00523341
- Testing
- Denosumab
- Volunteers
- 4,550 people
- Sponsor
- Amgen
Osteoporosis
Study of the Experience of Patients With Osteoporosis Using the Forteo B Pen to Self Administer Once Daily Teriparatide Therapy
This study is being conducted to collect information from subjects with osteoporosis regarding their experience using the Forteo B Pen to self-administer teriparatide in the community setting.
- Trial name
- NCT00577863
- Testing
- teriparatide
- Where
- 18 sites in United States
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Osteoporosis
IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)
The primary objective of this study is to assess the impact of physician's reinforcement using bone marker data on the subject's compliance (at least 50% drug taken) and persistence on treatment after one year in postmenopausal…
- Trial name
- NCT00268632
- Testing
- risedronate
- Sponsor
- Sanofi
Osteoporosis
Efficacy and Safety of AAE581 in Postmenopausal Women With Osteopenia/Osteoporosis.
AAE581 is a specific inhibitor of the cysteine protease cathepsin K. This trial is designed to provide detailed information about the effects( efficacy and safety) of AAE581 on Bone Mineral Density.
- Trial name
- NCT00170911
- Testing
- AAE581
- Volunteers
- 160 people
- Sponsor
- Novartis Pharmaceuticals
Postmenopausal Osteoporosis
A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis
This observational study will assess the compliance and persistence of patients, real life efficacy and safety of intravenously quarterly administered 3 mg ibandronate [Bonviva/Boniva] in comparison to oral alendronate generics…
- Trial name
- NCT01128257
- Testing
- alendronate, ibandronate [Bonviva/Boniva]
- Where
- Germany
- Volunteers
- 6,054 people
- Sponsor
- Hoffmann-La Roche
Osteoporosis, Postmenopausal
Satisfaction and Compliance of Risedronate in PMO
Compare subject satisfaction of once a week dosing of 35 mg Risedronate to once daily dosing of 5 mg Risedronate in postmenopausal osteoporotic women.
- Trial name
- NCT00549965
- Testing
- Risedronate Sodium
- Where
- South Korea
- Volunteers
- 202 people
- Sponsor
- Sanofi
Low Bone Density
Clinical Deployment and Validation of Rho
Osteoporosis is a widespread disease characterized by the loss of bone mineral density (BMD). 16 Bit has developed software, called RhoTM, that analyzes various x-rays, performed in patient age 50 and above for any clinical…
- Trial name
- NCT05245851
- Testing
- Opportunistic screening for low BMD
- Where
- 2 sites in Canada
- Volunteers
- 1,146 people
- Sponsor
- 16 Bit Inc.
Osteoporosis, Postmenopausal
Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis
The purpose of this study is to compare the effect of arzoxifene to raloxifene on the bone mineral density (bone strength).
- Trial name
- NCT00383422
- Testing
- Arzoxifene, Raloxifene
- Where
- 21 sites in United States, Argentina and 6 more
- Volunteers
- 320 people
- Sponsor
- Eli Lilly and Company